We have transitioned about 8 patients from other braf / mek agents to the Braf-tovi & Mek-tovi & they are doing very well in regard to tolerablitliy and not having reoccurrences of the AE’s that were dlt’s & drug holds on prior therapies.
Have you transitioned any patients?
How are patients doing on BRAFtovi & Mektovi?
Thoughts on how you will proceed with starting BRAF/ Mek therapies as we move forward?